FACT SHEET
Summary of Venous Thromboembolism (VTE) Measure Changes
for 01/01/2013 + Discharges

- VTE-1= Venous Thromboembolism Prophylaxis
- VTE-2= Intensive Care Unit Venous Thromboembolism Prophylaxis
- VTE-3= Venous Thromboembolism Patients with Anticoagulation Overlap Therapy

The information below consists of clarifications and changes in abstraction instructions.

Data Element or Table:  ICU VTE Prophylaxis
- Select allowable value ‘8’ if Eliquis® (apixaban) is administered on the day of or day after ICU admission or transfer, or the day of or the day after surgical end date, for those surgeries that occurred on the day of or the day after ICU admission or transfer.

Data Element or Table:  VTE Prophylaxis
- Select allowable value ‘8’ if Eliquis® (apixaban) is administered on the day of or day after hospital admission, or the day of or the day after surgical end date, for those surgeries that occurred on the day of or the day after hospital admission.

Data Element or Table:  Overlap Therapy
Reason why parenteral anticoagulation therapy and warfarin were not administered on the same day.
- Select allowable value “2” if Eliquis® (apixaban) is administered.

The manual for Hospital Inpatient Department Quality Measures can be found at:
http://www.qualitynet.org/dcs/ContentServer?c=Page&pagename=QnetPublic%2FPage%2FQnetTier4&cid=1228767363466
OR

This material was prepared by Oklahoma Foundation for Medical Quality, the Medicare Quality Improvement Organization for Oklahoma, under contract with the Centers for Medicare & Medicaid Services (CMS), an agency of the U.S. Department of Health and Human Services. This material is in alignment with The Joint Commission (TJC) specifications. The aligned manual represents the result of efforts by CMS and TJC to share a common set of performance measure specifications. The contents presented do not necessarily reflect CMS policy. 10SOW-SPOK01-1629-OK-0213